共 50 条
- [41] Phase I study of gefitinib and rapamycin in adult patients with recurrent glioblastoma multiforme (GBM).MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3462S - 3462SPhuphanich, SurasakChu, RayYu, John S.Black, Keith L.
- [42] Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioblastoma multiforme (GBM).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Shih, Kent C.Patel, Manish R.Butowski, Nicholas A.Bacha, Jeffrey A.Brown, DennisGarner, William J.Stelno, AnneSchwartz, Richard StephenKanekal, SarathLopez, LorenaBurris, Howard A.
- [43] PHASE I/II STUDY OF DIANHYDROGALACTITOL IN PATIENTS WITH RECURRENT MALIGNANT GLIOBLASTOMA MULTIFORME (GBM)NEURO-ONCOLOGY, 2014, 16Shih, KentPatel, ManishButowski, NicholasBacha, JeffreyBrown, DennisGarner, WilliamSteino, AnneSchwartz, RichardKanekal, SarathLopez, LorenaBurris, Howard A., III
- [44] PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) plus BEVACIZUMAB (BEV) IN BEV-NAIVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)NEURO-ONCOLOGY, 2018, 20 : 10 - 10Reardon, DavidKaley, ThomasDietrich, JorgClarke, JenniferDunn, GavinLim, MichaelCloughesy, TimGan, HuiPark, AndrewSchwarzenberger, PaulRicciardi, ToniMacri, MaryRyan, AileenVenhaus, Ralph
- [45] Phase II study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM): Results for cohort B (durvalumab monotherapy), bevacizumab-naive patients with recurrent GBMCANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)Reardon, David A.Kaley, ThomasDietrich, JorgLim, MichaelDunn, Gavin P.Gan, Hui K.Cloughesy, TimothyClarke, Jennifer L.Park, AndrewMacri, MaryRyan, AileenRicciardi, ToniReddy, VijayVenhaus, Ralph
- [46] PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBMNEURO-ONCOLOGY, 2018, 20 : 13 - 14Alexander, BrianSupko, JeffreyAgar, NathalieAhluwalia, ManmeetDesai, AratiDietrich, JorgKaley, ThomasPeereboom, DavidTakebe, NaokoDesideri, SerenaFisher, JoySims, MeganYe, XiaobuLigon, KeithNabors, L. BurtGrossman, StuartWen, Patrick
- [47] Efficacy and safety study of fotemustine and bevacizumab in patients with recurrent glioblastoma.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Escudero, Laura SanchezUrbano, Maria AmorGarces, Maria Yeray RodriguezMurillo, Fatima Toscano
- [48] Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin I (XPOI) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Martignetti, JohnRazak, Albiruni R. A.Chen, YingGabrail, Nashat Y.Gerecitano, John F.Camacho, CatalinaPereira, ElenaDottino, Peter RemsenShacham, SharonMcCauley, DilaraRashal, TamiSaint-Martin, Jean-RichardShacham, EranVincett, DarcyKauffman, MichaelMirza, Mansoor RazaSorensen, Morten
- [49] A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK InhibitorsBLOOD, 2021, 138Tantravahi, Srinivas K.Kim, Soo JinSundar, DivyaPatel, Ami B.Pomicter, Anthony D.Boucher, Kenneth M.Chamoun, KamalShah, JatinRets, AntonGeorge, Tracy I.Prchal, Josef T.Deininger, Michael W.
- [50] Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Alexander, Brian MichaelAhluwalia, Manmeet SinghDesai, Arati SuvasDietrich, JorgKaley, Thomas JosephPeereboom, David M.Takebe, NaokoSupko, Jeffrey G.Desideri, SerenaFisher, Joy D.Sims, MeganYe, XiaobuNabors, Louis B.Grossman, Stuart A.Wen, Patrick Y.